Security
Erasca, Inc. Common Stock · ERAS
ERASNASDAQCommon stockCurrentCIK 1761918Updated Oct 19, 2026
ERAS price & chart
Loading TradingView…
NASDAQ:ERAS on TradingView ↗About the company
At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of patients with cancer. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.
In the news
Important Notice to Long-Term Shareholders of Beta Bionics, Inc. (NASDAQ: BBNX); Better Home & Finance Holding Company (NASDAQ: BETR); Erasca, Inc. (NASDAQ: ERAS); and Insulet Corporation (NASDAQ: PODD): Grabar Law Office is Investigating Claims on Your Behalf ↗
Erasca, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Reed Kathrein at Hagens Berman Sobol Shapiro LLP By Application Deadline ↗
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Erasca, Inc. of Class Action Lawsuit and Upcoming Deadlines - ERAS ↗
Recent filings
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02
144 filing
Other Events
Items 8.01
144 filing
4 filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 420,401,000Source | 528,896,000Source | 435,054,000Source | 445,386,000Source | 525,744,000Source | 461,234,000Source | 471,244,000Source | 370,022,000Source | 396,154,000Source | 502,526,000Source | 395,297,000Source | 514,909,000Source |
| Property, Plant and Equipment, NetUSD | 14,037,000Source | 17,153,000Source | 11,916,000Source | 14,825,000Source | 17,990,000Source | 12,612,000Source | 15,587,000Source | 21,358,000Source | 13,303,000Source | 16,321,000Source | 22,327,000Source | 24,815,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 70,230,000Source | 68,885,000Source | 42,542,000Source | 66,143,000Source | 172,802,000Source | 47,256,000Source | 70,482,000Source | 76,726,000Source | 73,805,000Source | 67,739,000Source | 93,075,000Source | 284,217,000Source |
| Assets, CurrentUSD | 299,925,000Source | 330,174,000Source | 278,442,000Source | 310,660,000Source | 418,005,000Source | 253,784,000Source | 314,617,000Source | 306,623,000Source | 286,239,000Source | 308,793,000Source | 320,676,000Source | 444,496,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 11,525,000Source | 11,262,000Source | 9,704,000Source | 9,999,000Source | 9,593,000Source | 9,996,000Source | 10,032,000Source | 8,938,000Source | 10,164,000Source | 10,484,000Source | 8,326,000Source | 8,876,000Source |
| Operating Lease, Right-of-Use AssetUSD | 30,081,000Source | 32,891,000Source | 27,476,000Source | 30,814,000Source | 33,546,000Source | 28,265,000Source | 31,525,000Source | 37,177,000Source | 29,030,000Source | 32,218,000Source | 37,861,000Source | 40,418,000Source |
| Other Assets, NoncurrentUSD | 1,968,000Source | 3,879,000Source | 1,279,000Source | 2,591,000Source | 3,959,000Source | 1,446,000Source | 2,615,000Source | 4,456,000Source | 1,453,000Source | 2,622,000Source | 4,383,000Source | 4,772,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 72,515,000Source | 78,854,000Source | 73,185,000Source | 73,128,000Source | 74,657,000Source | 67,706,000Source | 71,742,000Source | 81,613,000Source | 70,983,000Source | 79,027,000Source | 78,611,000Source | 103,056,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | — | — |
| Common Stock, Value, IssuedUSD | 28,000Source | 28,000Source | 31,000Source | 28,000Source | 27,000Source | 31,000Source | 28,000Source | 15,000Source | 28,000Source | 28,000Source | 15,000Source | 15,000Source |
| Retained Earnings (Accumulated Deficit)USD | -863,117,000Source | -735,431,000Source | -1,119,728,000Source | -832,505,000Source | -704,231,000Source | -1,075,649,000Source | -798,629,000Source | -641,030,000Source | -892,209,000Source | -767,663,000Source | -606,013,000Source | -480,971,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 649,000Source | 1,825,000Source | -1,249,000Source | 415,000Source | -196,000Source | -699,000Source | 628,000Source | -210,000Source | 628,000Source | 405,000Source | 77,000Source | -1,041,000Source |
| Stockholders' Equity Attributable to ParentUSD | 347,886,000Source | 450,042,000Source | 361,869,000Source | 372,258,000Source | 451,087,000Source | 393,528,000Source | 399,502,000Source | 288,409,000Source | 325,171,000Source | 423,499,000Source | 316,686,000Source | 411,853,000Source |
| Additional Paid in Capital, Common StockUSD | 1,210,326,000Source | 1,183,620,000Source | 1,482,815,000Source | 1,204,320,000Source | 1,155,487,000Source | 1,469,845,000Source | 1,197,475,000Source | 929,634,000Source | 1,216,724,000Source | 1,190,729,000Source | 922,607,000Source | 893,850,000Source |
| Liabilities and EquityUSD | 420,401,000Source | 528,896,000Source | 435,054,000Source | 445,386,000Source | 525,744,000Source | 461,234,000Source | 471,244,000Source | 370,022,000Source | 396,154,000Source | 502,526,000Source | 395,297,000Source | 514,909,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 28,712,000Source | 30,025,000Source | 33,571,000Source | 28,151,000Source | 24,893,000Source | 26,664,000Source | 25,471,000Source | 30,243,000Source | 28,511,000Source | 31,395,000Source | 26,156,000Source | 48,690,000Source |
| Operating Lease, Liability, CurrentUSD | 4,885,000Source | 4,450,000Source | 5,441,000Source | 4,709,000Source | 4,286,000Source | 5,251,000Source | 4,791,000Source | 4,126,000Source | 5,066,000Source | 4,619,000Source | 3,970,000Source | 1,305,000Source |
| Accounts Payable, CurrentUSD | 3,029,000Source | 2,405,000Source | 2,022,000Source | 1,663,000Source | 2,142,000Source | 2,163,000Source | 2,262,000Source | 2,633,000Source | 981,000Source | 468,000Source | 2,000,000Source | 23,049,000Source |
| Operating Lease, Liability, NoncurrentUSD | 43,408,000Source | 48,489,000Source | 39,273,000Source | 44,714,000Source | 49,682,000Source | 40,702,000Source | 46,020,000Source | 50,811,000Source | 42,073,000Source | 47,270,000Source | 51,889,000Source | 53,793,000Source |
| Other Liabilities, NoncurrentUSD | 395,000Source | 340,000Source | 341,000Source | 263,000Source | 82,000Source | 340,000Source | 251,000Source | 559,000Source | 399,000Source | 362,000Source | 566,000Source | 573,000Source |
| Additional Financial Items | ||||||||||||
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 362,400,000Source | 318,900,000Source | 384,300,000Source | 386,700,000Source | 408,400,000Source | 408,500,000Source | 304,600,000Source | 297,700,000Source | 341,800,000Source | 298,300,000Source | 312,400,000Source | 435,600,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -183,440,000Source | -30,966,000Source | -124,546,000Source | -161,650,000Source | -125,042,000Source | -242,805,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | 755,000Source | 842,000Source | 716,000Source | 787,000Source | 723,000Source | 822,000Source | 3,107,000Source | 3,805,000Source | 3,732,000Source | 2,641,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 8,460,000Source | 6,713,000Source | 24,899,000Source | 26,973,000Source | 26,231,000Source | 20,109,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 1,182,000Source | 1,794,000Source | 513,000Source | -1,532,000Source | -886,000Source | 676,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -27,383,000Source | -31,555,000Source | -95,455,000Source | -109,417,000Source | -101,217,000Source | -103,264,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -243,830,000Source | 34,265,000Source | 100,425,000Source | -156,616,000Source | -91,220,000Source | -71,081,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 36,000Source | 83,000Source | 128,000Source | 60,000Source | 1,775,000Source | 14,551,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 244,664,000Source | 33,000Source | 1,096,000Source | 240,697,000Source | 1,295,000Source | 98,075,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -26,549,000Source | 2,743,000Source | 6,066,000Source | -25,336,000Source | -191,142,000Source | -76,270,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 70,638,000Source | 69,293,000Source | 42,950,000Source | 66,551,000Source | 47,664,000Source | 70,890,000Source | 74,213,000Source | 68,147,000Source | 93,483,000Source | 284,625,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 5,965,000Source | 6,637,000Source | 9,606,000Source | 6,398,000Source | 8,460,000Source | 6,713,000Source | 24,899,000Source | 26,973,000Source | 26,231,000Source | 20,109,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 362,400,000Source | 318,900,000Source | 384,300,000Source | 386,700,000Source | 408,500,000Source | 304,600,000Source | 341,800,000Source | 298,300,000Source | 312,400,000Source | 435,600,000Source |
| General and Administrative ExpenseUSD | — | — | 10,072,000Source | 9,611,000Source | 11,719,000Source | 9,455,000Source | 10,646,000Source | 9,661,000Source | 38,551,000Source | 41,728,000Source | 37,704,000Source | 32,993,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -30,612,000Source | -31,200,000Source | -44,079,000Source | -33,876,000Source | -183,440,000Source | -30,966,000Source | -124,546,000Source | -161,650,000Source | -125,042,000Source | -242,805,000Source |
| Nonoperating Income (Expense)USD | — | — | 3,934,000Source | 6,042,000Source | 3,540,000Source | 4,249,000Source | 4,471,000Source | 4,664,000Source | 16,359,000Source | 17,937,000Source | 16,483,000Source | 4,645,000Source |
| Operating ExpensesUSD | — | — | 34,546,000Source | 37,242,000Source | 47,619,000Source | 38,125,000Source | 187,911,000Source | 35,630,000Source | 140,905,000Source | 179,587,000Source | 141,525,000Source | 247,450,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -37,000Source | 173,000Source | — | — | 22,000Source | -76,000Source | — | — | — | -257,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 258,750,000Source | — | — | — | — | 95,251,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 1,958,000Source | 33,000Source | 372,000Source | 836,000Source | 505,000Source | 2,004,000Source |
| Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss | — | — | — | — | — | — | —Source | — | — | — | — | — |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale | — | — | — | — | — | — | —Source | —Source | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -34,546,000Source | -37,242,000Source | -47,619,000Source | -38,125,000Source | -187,911,000Source | -35,630,000Source | -140,905,000Source | -179,587,000Source | -141,525,000Source | -247,450,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -37,000Source | 173,000Source | — | — | 22,000Source | -76,000Source | — | — | — | -257,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | -124,546,000Source | — | — | — |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -30,612,000Source | -31,200,000Source | -44,079,000Source | -33,876,000Source | -183,440,000Source | -30,966,000Source | -124,546,000Source | -161,650,000Source | -125,042,000Source | -242,805,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.11Source | -0.11Source | -0.14Source | -0.12Source | -0.6Source | -0.11Source | -0.44Source | -0.69Source | -0.83Source | -1.99Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.11Source | -0.11Source | -0.14Source | -0.12Source | -0.6Source | -0.11Source | -0.44Source | -0.69Source | -0.83Source | -1.99Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 283,681,570Source | 282,384,964Source | 311,336,806Source | 283,355,730Source | 304,317,460Source | 283,260,289Source | 283,533,696Source | 233,817,916Source | 150,184,994Source | 122,024,848Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 283,681,570Source | 282,384,964Source | 311,336,806Source | 283,355,730Source | 304,317,460Source | 283,260,289Source | 283,533,696Source | 233,817,916Source | 150,184,994Source | 122,024,848Source |
| Additional Financial Items | ||||||||||||
| Common Stock, Dividends, Per Share, DeclaredUSD per share | — | — | — | — | — | — | 0Source | — | 0Source | 0Source | 0Source | 0Source |
| General and Administrative ExpenseUSD | — | — | 10,072,000Source | 9,611,000Source | 11,719,000Source | 9,455,000Source | 10,646,000Source | 9,661,000Source | 38,551,000Source | 41,728,000Source | 37,704,000Source | 32,993,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -124,495,000Source | — | — | — |
| Interest Income (Expense), Nonoperating, NetUSD | — | — | 3,971,000Source | 5,869,000Source | 3,603,000Source | 4,330,000Source | 4,449,000Source | 4,740,000Source | 16,607,000Source | 20,093,000Source | 16,712,000Source | 4,902,000Source |
| Nonoperating Income (Expense)USD | — | — | 3,934,000Source | 6,042,000Source | 3,540,000Source | 4,249,000Source | 4,471,000Source | 4,664,000Source | 16,359,000Source | 17,937,000Source | 16,483,000Source | 4,645,000Source |
| Operating ExpensesUSD | — | — | 34,546,000Source | 37,242,000Source | 47,619,000Source | 38,125,000Source | 187,911,000Source | 35,630,000Source | 140,905,000Source | 179,587,000Source | 141,525,000Source | 247,450,000Source |
| Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss | — | — | — | — | — | — | —Source | — | — | — | — | — |
Offerings
Registration 333-297427
Filing attachments
eras-ex99_1.htm · 8-K · 2026-08-11
EX-99.1 2 eras-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Erasca Reports Second Quarter 2026 Business Updates and Financial Results Updated ERAS-0015 data in U.S. trial highlighted compelling monotherapy efficacy in 2L+ KRAS G12X PDAC and continued favorable tolerability, as well as further advancement of panitumumab CRC combination ERAS-0015 program advancing toward three potentially registration-enabling trials in pancreatic and lung cancers Additional ERAS-0015 monotherapy and combinati…
Read attachment ↗d371010dex991.htm · 8-K · 2026-07-14
EX-99.1 4 d371010dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Erasca Announces Proposed Public Offering of $500 Million of Common Stock July 13, 2026 SAN DIEGO, July 13, 2026 (GLOBE NEWSWIRE) - Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that it intends to offer and sell, subject to market and other conditions, $500.0 mill…
Read attachment ↗d371010dex992.htm · 8-K · 2026-07-14
EX-99.2 5 d371010dex992.htm EX-99.2 EX-99.2 Exhibit 99.2 Erasca Announces Pricing of Upsized Public Offering of Common Stock SAN DIEGO, July 13, 2026 (GLOBE NEWSWIRE) - Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the pricing of an upsized public offering of 31,428,572 shares of its common stock. The shares of common st…
Read attachment ↗d133579dex44.htm · S-3ASR · 2026-07-13
Exhibit 4.4 ERASCA, INC. INDENTURE Dated as of ___________, 20___ [____________] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. …
Read attachment ↗eras-ex99_1.htm · 8-K · 2026-05-11
EX-99.1 2 eras-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Erasca Reports First Quarter 2026 Business Updates and Financial Results Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted agents ERAS-0015 monotherapy expansion and combination dose escalation data expected in H1 2027; ERAS-4001 Phase 1 preliminary monotherapy data expected in H2 …
Read attachment ↗eras-ex99_1.htm · 8-K · 2026-03-12
EX-99.1 2 eras-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Erasca Reports Fourth Quarter and Full Year 2025 Business Updates and Financial Results Encouraging early clinical activity observed during ERAS-0015 dose escalation, including ongoing responses across multiple RAS-mutant tumors with favorable safety, tolerability, and pharmacokinetics Phase 1 monotherapy data for ERAS-0015 expected in H1 2026 and for ERAS-4001 in H2 2026 Successfully completed $259 million upsized financing in Janu…
Read attachment ↗